[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Christian Medical College and Hospital, Ludhiana, India\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":76},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100611678","phase-3-reducing-the-burden-of-cardiovascular-events-with-antiplatelet-therapy-in-patients-with-intracerebral-haemorrhage-100611678",false,"NCT07243704","Reducing the Burden of Cardiovascular Events With Antiplatelet Therapy in Patients With IntraCerebral Haemorrhage","Reducing the Burden of Cardiovascular Events With Antiplatelet Therapy in Patients With IntraCerebral Haemorrhage.","BEAT-ICH","Inclusion Criteria:\n\n* Age ≥18 years\n* First-ever Intracerebral Haemorrhage\n* Presenting ≥24 hrs up to 3 months of stroke symptoms confirmed by brain imaging\n* CT \u002FMRI confirming Intracerebral Haemorrhage\n* Alive ≥24 hours after non-traumatic ICH\n\nExclusion Criteria:\n\n* ICH is known to be due to trauma, a structural cause (e.g., aneurysm, arteriovenous malformation, cerebral cavernous malformation, venous thrombosis, or tumour), or haemorrhagic transformation of cerebral infarction\n* Glasgow coma score ≤5\n* Taking any antiplatelet or anticoagulant therapy 15 days prior to randomization.\n* Women pregnant, breastfeeding, childbearing potential, and not using contraceptives\n* Enrolled in any other clinical trial\n* Sick or compromised patients with life expectancy of less than a year\n* Geographical or other factors that prohibit long-term follow-up","ALL","18 Years","99 Years",{"count":21,"type":22},5676,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","BEAT ICH will be a pragmatic, randomised, placebo-controlled, blinded, superiority clinical trial aiming to recruit 5676 patients aged ≥18 years who survive ICH and assign them 1:1 to starting antiplatelet monotherapy (Aspirin 75 mg od) versus placebo for the entire duration of the trial for preventing MACE. Recruitment duration is for 2.5 years. The duration of the medication and follow-up will vary based on recruitment timeline. If recruited during the first year of the trial, the patient will take the medication for three years or until the trial ends or an event occurs, with a matching follow-up period. If recruited towards the end of the trial, he\u002Fshe will take the medication for six months and be followed up for the same duration. The trial's follow-up duration is three years. The patients will be recruited for 2.5 years, and the last recruit will have a minimum follow-up of six months. No new patients will be recruited within the last six months of the trial, but all the patients will be followed up until the end of the trial.",[28],"Intracerebral Haemorrhage",[30,28,31,32,33,34,35],"stroke","antiplatelet","Major adverse cardiovascular and cerebrovascular events","Randomized control trial","Secondary Prevention","Recurrent stroke","NOT_YET_RECRUITING","2026-02-05",{"date":39,"type":40},"2026-02-09","ACTUAL",{"date":42,"type":22},"2026-02-15",{"date":44,"type":22},"2029-02-14",{"name":46,"class":47},"Christian Medical College and Hospital, Ludhiana, India","OTHER",40,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100503559","phase-4-indian-trial-of-tranexamic-acid-in-spontaneous-intracerebral-haemorrhage-100503559","NCT05836831","Indian Trial of Tranexamic Acid in Spontaneous Intracerebral Haemorrhage","Inclusion Criteria:\n\nAdult patients aged more than 18 years, presenting with non- traumatic intracerebral haemorrhage within 4.5 hours of onset of stroke symptoms\n\nExclusion Criteria:\n\n1. Patients with ICH secondary to anticoagulation, thrombolysis, or known underlying structural abnormality such as arteriovenous malformation, aneurysm, tumor, venous thrombosis or due to known hereditary coagulation disorders.\n2. Contraindication to TXA.\n3. Concurrent participation in another trial.\n4. Pre-stroke life expectancy \\\u003C3 months (e.g. advanced metastatic cancer).\n5. Glasgow coma scale (GCS) ⩽5.\n6. ICH secondary to trauma.\n7. Women of childbearing potential, pregnant, or breastfeeding at randomization.\n8. Geographical or other factors that prohibit follow-upto 90 days.\n9. Concurrent or planned treatment with any other hemostatic agents.\n10. ICH volume \\>60 mL as measured by ABC\u002F2 method.",{"count":56,"type":22},3400,[58],"PHASE4","This multicenter, pragmatic randomized, open-label clinical trial aims to assess whether Tranexamic Acid improves outcomes in adult patients with spontaneous intracerebral haemorrhage.\n\nThe participants presenting within 4.5 hours of the onset of symptoms of stroke with intracerebral haemorrhage confirmed on Computed Tomography (CT Scan) will be randomized into two groups in a 1:1 ratio using a central online randomization. The treatment arm will consist of giving intravenously 2 grams of Tranexamic Acid in 100 ml 0.9% sodium chloride administered over 45 minutes. Control arm patients will receive standard of care treatment as per the institutional protocol. In both arms, intensive systolic blood pressure reduction to less than 140 mmHg will be done using antihypertensive medications, which has to be achieved within one hour and will be maintained over next seven days. The choice of antihypertensive drug will depend on the clinician's preference.\n\nBoth groups will have a repeat CT scan after 24 hours to check for any increase in the haematoma volume. Any deterioration in the neurological status will warrant urgent brain imaging. On day 7, the patient will be assessed for their NIHSS score and mRS score. On day 90, quality of life and the functional outcome will be assessed.",[61],"Intracerebral Hemorrhagic Stroke",[63,64,65],"Stroke","Spontaneous Intracerebral Haemorrhage","Tranexamic acid","RECRUITING","2026-01-21",{"date":69,"type":40},"2026-01-22",{"date":71,"type":40},"2022-08-30",{"date":73,"type":22},"2026-11",{"name":46,"class":47},48,""]